239095-84-2

Usage

Uses

Used in Pharmaceutical Industry:
2,3-dibromo-6,7-dichloro-1,2,3,4-tetrahydroquinoxaline is used as a central nervous system depressant for its potential calming and sedative effects on the nervous system.
Used in Antimicrobial Applications:
In the pharmaceutical industry, 2,3-dibromo-6,7-dichloro-1,2,3,4-tetrahydroquinoxaline is utilized for its antimicrobial activity, making it a candidate for the development of new antibiotics or antifungal agents.
Used in Organic Synthesis:
2,3-dibromo-6,7-dichloro-1,2,3,4-tetrahydroquinoxaline is employed as an intermediate in organic synthesis, particularly for the development of complex organic molecules and pharmaceutical compounds.
Used in Drug Development:
Due to its potential pharmacological properties, 2,3-dibromo-6,7-dichloro-1,2,3,4-tetrahydroquinoxaline is used in drug development for the creation of new therapeutic agents, targeting various medical conditions.
Under specific conditions and in controlled environments, 2,3-dibromo-6,7-dichloro-1,2,3,4-tetrahydroquinoxaline demonstrates promising potential for various applications in medicinal and pharmaceutical chemistry, making it a valuable compound for further research and development.

InChI:InChI=1/C8H6Br2Cl2N2/c9-7-8(10)14-6-2-4(12)3(11)1-5(6)13-7/h1-2,7-8,13-14H

Upstream product

• 5348-42-5 4,5-Dichloro-1,2-phenylenediamine 
• 25983-13-5 6,7-dichloro-1,4-dihydroquinoxaline-2,3-dione 

Downstream Products

• 239094-83-8 N'-[3-(1-benzenesulfonyl-1H-indol-2-yl)-6,7-dichloro-quinoxalin-2-yl]-N,N-diethyl-butane-1,4-diamine 
• 239094-97-4 N1-(3-([2,2’-bithiophen]-5-yl)-6,7-dichloroquinoxalin-2-yl)-N4,N4-diethylbutane-1,4-diamine 

Relevant academic research and scientific papers

Synthesis and structure-activity relationship of 2-amino-3-heteroaryl-quinoxalines as non-peptide, small-molecule antagonists for interleukin-8 receptor

Interleukin-8 modulation is implicated in many inflammatory and cancer diseases. Starting from a mass-screening hit, the synthesis and structure-activity relationship of 2-amino-3-heteroarylquinoxalines as non-peptide, small molecule interleukine-8 receptor antagonists have been developed. The optimized derivatives, PD 0210293 (13y) and PD 0220245 (13r), show inhibition of both IL-8 receptor binding and IL-8-mediated neutrophil chemotaxis.

Substituted quinoxaline derivatives as interleukin-8 receptor antagonists

Quinoxaline compounds are described as well as methods for the preparation and pharmaceutical compositions of same, which are useful as interleukin-8 (IL-8) receptor antagonists and can be used in the treatment of a chemokine-mediated disease wherein the chemokine binds to an IL-8a (CXCR1) or b (CXCR2) receptor such as a chemokine-mediated disease selected from psoriasis, or atopic distress syndrome, arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, gastric ulcer, septic shock, endotoxic shock, gram-negative sepsis, toxic shock syndrome, stroke, cardiac and renal reperfusion injury, glomerulo-nephritis, or thrombosis, Alzheimer's disease, graft versus host reaction, allograft rejections, or allergic diseases.